AGP Picks
View all

STEM Minnesota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Minnesota.

Press releases published on June 8, 2026

NeckCare Home unlocks a new marketing advantage that their local competitors can’t match
Capricor Therapeutics to Present at Upcoming Investor Conferences
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Motivosity Recognized as a 2026 Top Workplaces Culture Excellence Award Winner
Lexful Closes $7M Seed Round for Next-Generation Documentation for MSPs
DataSnipper Awarded Texas Department of Information Resources Contract Through Carahsoft
Crunchafi Launches In-App Integration with Thomson Reuters Guided Assurance, Bringing Lease Accounting Automation Directly into PPC Audit Workflows
Broadcom Expands Its Investment in Spring and Java Ecosystem Security to Prepare Customers for AI-Enabled Threats
Fieldguide Launches Field Orchestrator, Marking the Next Phase of Agentic AI in Audit
Kanza AI’s Clinical Reasoning System Launches with Lightning AI on NVIDIA Infrastructure in the US
ASUS Announces ProArt PZ14, Now Available in the United States
OUTDOOR HOLDING COMPANY TO CONDUCT FOURTH QUARTER EARNINGS CALL ON JUNE 22, 2026 AT 9:00 AM ET
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress
Mavenir and TextNow Win Best MVNO and Industry Collaboration at MVNOs World Awards
Pushpay Introduces a Streamlined Customer Experience Between Pushpay and Nurture.io Platforms
Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease
Nexera Technologies: Subsidiary Fort Technology Commences Trading on Nasdaq Under Ticker “FRTT” Today
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Foresight Secures $17.5 Million Strategic Investment from VisionWave at a $34 Million Valuation Post Investment to Advance AI Perception Capabilities for Defense and Security

Share this page:

Sign up for:

STEM Minnesota

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.